BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
©Author(s) (or their employer(s)) 2026.
World J Crit Care Med. Mar 9, 2026; 15(1): 114620
Published online Mar 9, 2026. doi: 10.5492/wjccm.v15.i1.114620
Table 3 Analysis of vaccines doses and booster doses with post coronavirus disease 2019 diseases, n (%)
Total number of vaccines
TotalP value
0
1
2
3 and above
11 (1.04)103 (9.79)122 (11.59)816 (77.57)1052 (100)
Ongoing treatment for post COVID-19 complicationYes2 (18.2)3 (2.9)8 (6.6)38 (4.7)51 (4.8)0.116
Ongoing management for type of complicationsComplications developed after COVID-191 (9.1)1 (1.0)7 (5.7)24 (2.9)33 (3.1)0.21
Post-COVID management of pre-existing conditions1 (9.1)2 (1.9)1 (0.8)14 (1.7)18 (1.7)
Disease developed after COVID-19Yes2 (18.2)12 (11.7)19 (15.6)117 (14.3)150 (14.3)0.81


Write to the Help Desk